Cartesian Therapeutics (RNAC) has shared an update.
Cartesian Therapeutics, Inc. faces a significant shift as Audentes Therapeutics, Inc. (Astellas) has decided to terminate their licensing and development partnership, effective June 6, 2024. This termination releases Cartesian from future financial obligations regarding their Xork product candidate, which was aimed at treating Pompe disease alongside Astellas’ gene therapy. Although the initial agreement included a potential for Cartesian to earn up to $340 million in milestone payments and royalties, these prospects are now off the table with no penalties incurred for the early termination.
See more data about RNAC stock on TipRanks’ Stock Analysis page.
